KEYPOINTS
Pyk2 plays a tumor-promoting role in MM progression via modulation of Wnt/ β -catenin signaling pathway.
Pyk2 inhibitors represent a new therapeutic option against MM.
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INTRODUCTION
Multiple Myeloma represents a model of hematological malignancy where continuous cell dissemination and tumor progression occurs through trafficking of tumor cells in and out of the bone marrow. 1 ,2 Yet, the mechanisms by which malignant plasma cells metastasize and disseminate to different areas of the bone marrow are not well understood. In solid tumors, one of the master regulators of tumor metastasis and dissemination is the focal adhesion kinase proteins.
The focal adhesion kinase (FAK) family is composed of FAK and Proline-rich tyrosine kinase 2 (Pyk2) that share homology at the structural level. It has been proposed that FAK is overexpressed in a large number of tumors and promotes multiple malignant processes, such as tumor cell growth, invasion, cancer stem cell self-renewal, metastasis and angiogenesis, through integrating extracellular stimuli of integrins and growth factor receptors with downstream signaling including Akt, Erk and NF-κB. 3 However, the role of the FAK-homolog Pyk2 in tumors remains less explored.
Pyk2 is also known as FAK2, RAFTK, CAKB and it is a non-receptor protein kinase that is structurally similar to FAK with 48% identity of acid amino, 60% identity of sequences in central kinase domain, and identical positions of four phosphorylation sites. 4, 5 FAK is expressed ubiquitously, indispensable for embryogenesis, co-localized at focal contacts with integrins and growth factor receptors, while Pyk2 is expressed restrictedly in endothelium, central nervous system and hematopoietic lineages, dispensable for organ development, localized throughout cytoplasm, and sensitive to intracellular Ca + signaling and G-coupled protein receptors. 4, [6] [7] [8] Pyk2
has been shown to interact with some of the proteins that FAK binds to, such as Src, Paxillin, [9] [10] [11] suggesting that they may be implicated in several overlapping signaling pathways. Intriguingly, studies reported that in the context of FAK depletion, endogenous Pyk2 expression in some cell types increased in a compensatory manner to partly maintain FAK effects in regulating cell motility and angiogenesis. 9, 12, 13 The specific role of Pyk2 in B cells has been shown in Pyk2 -/-mice, where Pyk2-deficient B cells and macrophages exhibit impaired mobility and responsiveness to chemokines. 14 A compensatory increase of FAK was not observed in these Pyk2-deficient cells. Pyk2 could be activated in FAK-deficient cells by binding to fibronectin and it is not dependent on extracellular matrix simulation that is used to activate FAK. 9, 15 More interestingly, Pyk2-deficient mice present with increased bone formation, due to the enhanced differentiation of osteoprogenitor cells. 16 Therefore, despite sharing structural identity with FAK, Pyk2 appears to differ from FAK in regulating cellular phenotypes and signaling pathways.
Given that Pyk2 is specifically expressed on hematopoietic cells, we sought to examine the role of Pyk2 in the regulation of cell dissemination and tumor progression in Multiple Myeloma as a representative hematological malignancy. Aberrant up-regulation of Pyk2 has been shown to correlate with poor prognosis in lung cancer and facilitate epithelial to mesenchymal transition in breast cancer. 17, 18 Nevertheless, the putative oncogenic role of Pyk2 in cancers in general and in specific hematologic malignancies has not been previously described.
In our study, we demonstrated that Pyk2 is highly expressed, at mRNA and protein levels, in MM patients compared to healthy individuals. By using gain-of and loss-of-function genetic studies together with pharmacological studies, we confirmed the tumor-promoting role of Pyk2, both in vitro and in vivo. Mechanistically, Pyk2 protected β -catenin from GSK3β-induced degradation, thus maintaining the activation of β -catenin signaling. Overall, our findings describe 
METHODS

Cells
Bone marrow stromal cells (BMSCs) were isolated from bone marrow (BM) samples from MM patients as described previously. 19 Andrew Kung, Dana-Farber Cancer Institute).
Generation of loss-and gain-of-function Pyk2 stable MM cell lines
Lentiviral Pyk2-shRNA (A2 and A4) and FAK-shRNA were obtained from The RNAi Consortium (TRC) (http://www.broadinstitute.org/rnai/trc) (see sequence in Table S1 ). A scramble shRNA was used as a control. For Pyk2-expressing lentiviral particles, a Pyk2-expressing vector (Genecopoeia, Rockville, MD) containing full length of Pyk2 cDNA (NM_004103.4) was packaged with lentiviral plasmids by using Lenti-Pac™ HIV Expression
Packaging Systems (Genecopoeia, Rockville, MD) according to manufacturer's instruction.
GFP + /luc + -MM.1S cells were transduced with lentiviral particles and polybrene at 8µg/ml (Sigma-Aldrich, St Louis, MO), followed by puromycin selection at 24 hours after the transduction. Efficiency of knockdown or overexpression was validated by immunoblotting. 
Gene expression analysis
To determine the gene expression of Pyk2 in plasma cells isolated from healthy donors or from MM patients in different subtypes including MGUS, Smoldering, active MM, we used published datasets (GSE2658) from the Gene Expression Omnibus. 20, 21 All the intensity files were MAS5 transformed and the data normalized to the median, as previously reported.
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Cell proliferation assay
Cell proliferation of Pyk2-knockdown or Pyk2-overexpressing MM.1S cells was measured by DNA synthesis using the [3H]-thymidine uptake assay (PerkinElmer, Waltham, MA) described previously. 19 For VS-4718 treated MM cells, cell proliferation was assayed using the CellTiter 96 Aqueous One Solution Proliferation assay (Promega, Madison, WI). Briefly, MM cells were seeded in 96-well regular culture plates using phenol-red-free culture media (Life Technologies, Grand Island, NY) or fibronectin coated-culture plates (BD Bioscience, San Jose, CA) in the presence of 10 ng/ml human IL-6. After overnight culture, VS-4718 was added in 1:3 serial dilutions. After 96h incubation, cell proliferation was measured. Dose-response curves were generated to determine EC 50 values of compounds using the GraphPad software (GraphPad Software, Inc., La Jolla, CA).
Cell cycle assay
Cells were stained with propidium iodine (Sigma-Aldrich, St Louis, MO) and cell cycle was determined using an Epics flow cytometry, as previously described. Assay kit (Millipore, Billerica, MA) was used according to the manufacturer's instruction.
Immunoblotting
Harvested cells were lysed using lysis buffer (Cell Signaling, Danvers, MA) for total cell lysates.
Nuclear fraction was isolated by using NE-PER Nuclear and Cytoplasmic Extraction Kit Cambridge, MA). Anti-IgG was used for negative control. Femurs of tumor-bearing mice were prepared and sectioned, followed by staining with anti-Pyk2 and anti-β-catenin (Santa Cruz, Dallas, Texas).
Pyk2 inhibitor
VS-4718 has been previously described as a FAK inhibitor. Following incubation with anti-mouse-IgG-HRP and subsequent TMB substrate, plates were read at 450 nm. 
In vivo studies
Statistical analysis
Data were analyzed using unpaired Student t tests comparing 2 conditions or a 1-way ANOVA with Bonferroni or Newman-Keuls correction for multiple comparisons. P < 0.05 was considered significant and tests were performed 2-sided. Data is presented as means and error bars in the figures depict standard deviation (SD).
RESULTS
Pyk2 is highly expressed in MM.
We examined the expression of Pyk2 and its homolog FAK, in MM patients and healthy individuals, both at mRNA and protein levels. First, we evaluated the mRNA level of Pyk2 and FAK in CD138 + cells derived from bone marrow of MM patients, using a published gene expression dataset (GSE2658). Pyk2 was significantly up-regulated in plasma cells obtained from MM patients compared to the related normal cellular counterpart isolated from healthy individuals. Importantly, higher levels of Pyk2 were also detected at the MGUS or smoldering myeloma stages ( Figure 1A) . Conversely, FAK expression in MM patients was down-regulated compared to the normal counterpart ( Figure 1B) . By immunohistochemistry performed on 14 MM and 6 normal bone marrow samples, we confirmed the up-regulation of Pyk2 in MM patients at the protein level (Figure 1C, 1D ; Supplemental Figure 1A ). Since Pyk2 is located in the chromosomal region of 8p21, where a deletion has been reported to occur in a small subset of MM patients, 27 we speculated that this deletion may affect the expression of Pyk2 in MM. We therefore analyzed the copy number status of 111 genes located in the region from 8p21.1 to 8p22 of a total of 27 MM cell lines enrolled in Cancer Cell Line Encyclopedia (CCLE) database, 28 and found that, in a small subset of MM cell lines, the copy number of these genes including Pyk2 were commonly lost ( Figure 1E and 1F), which partly reflected the instability of the 8p21 region. Moreover, Pyk2 mRNA levels were positively associated with the copy number ( Figure 1G ), suggesting 8p21 stability is important for Pyk2 expression. We also examined Pyk2 expression in 6 MM cell lines by immunoblotting. The Pyk2 expression pattern at the protein For personal use only. on October 4, 2017. by guest www.bloodjournal.org From level across these tested cells was consistent with their 8p21 stability. Specifically, U266 cells, which has loss of 8p21, exhibited low/absent expression of Pyk2 ( Figure 1H ).
Pyk2-silencing decreases MM tumor growth and prolongs survival in vivo.
To investigate whether Pyk2 is involved in MM tumor progression, we generated GFP For We then evaluated the possible molecular mechanism responsible for Pyk2-induced MM tumor growth. We first demonstrated that Pyk2 inhibition in MM cells led to significant increase of phosphorylated β -catenin and subsequent decrease of total β -catenin ( Figure 3E ). Cyclin D1
and c-Myc, that are well-known target genes of β -catenin signaling and defined oncogenes in MM, were shown to be decreased with the inhibition of Pyk2 ( Figure 3E ). This observation was
vivo on bone marrow specimens harvested from mice that were injected with Pyk2-knockdown cells ( Figure 3F ). Importantly, Pyk2 inhibition led to increased phosphorylated GSK3β responsible for increased phosphorylation of β -catenin, resulting in β -catenin degradation ( Figure 3E ). Moreover, we found that inhibition of Pyk2 resulted in decreased p-Akt ( Figure 3E ), suggesting Pyk2 may regulate β -catenin via modulating the PI3K/Akt/GSK3β pathway.
Wnt/β-catenin signaling is implicated in myeloma-bone marrow interaction, thus promoting MM disease development. 30 We therefore tested the role of Pyk2 in modulating Wnt/β-catenin signaling in MM cells in the context of the bone marrow milieu. MM-BMSCs induced Pyk2 phosphorylation, together with up-regulation of β -catenin and c-myc at the nuclear level in scramble cells. In contrast, BMSC-triggered nuclear c-Myc up-regulation was abolished in Pyk2-knockdown MM cells ( Figure 3G ). In addition, the phosphorylation of Src and Paxillin, known as FAK-binding proteins, was decreased in MM cells upon Pyk2-silencing ( Figure 3H ).
Pyk2-overexpression promotes MM tumor progression and reduces survival in vivo.
To further demonstrate the tumor-promoting role of Pyk2 in MM, we explored the effect of 
A novel dual FAK/Pyk2 inhibitor exerts anti-MM activity both in vitro and in vivo.
Based on the demonstration that Pyk2 plays a tumor-promoting role in MM, we evaluated the value of Pyk2 as a therapeutic target in MM, by testing a novel FAK/Pyk2 inhibitor VS-4718 (Verastem, Cambridge, MA). As shown in Figure 6A , VS-4718 is a potent inhibitor of FAK and Pyk2 kinase activities in both biochemical and cellular assays. We then specifically treated MM cells with VS-4718, and found VS-4718 significantly inhibited proliferation of MM.1S, H929
and RPMI8226 cells ( Figure 6B ). We next compared VS-4718-dependent modulation of apoptosis in MM cells with either high/Pyk2 (MM.1S) or low/Pyk2 levels (U266); and found significant induction of apoptosis on MM.1S cells compared to U266 cells, either in absence or presence of IL-6/fibronectin stimulation (Supplemental Fig. 2A-B ).
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The dose-dependent reduction of p-Pyk2 by VS-4718 in the MM.1S cell line was confirmed ( Figure 6C ).
We examined cell cycle profiling in VS-4718-treated cells, showing reduction of S-phase together in VS-4718 treated MM.1S cells which express high Pyk2. The same phenotype was not observed in U266 cells which express low Pyk2. We next evaluated p21 protein expression in high Pyk2 versus low Pyk2 cells upon VS-4718 treatment; and found that VS-4718 dosedependently inhibited p21 in MM.1S but not in U266 (Supplemental Figure 3) .
Previous studies have shown that Pyk2 leads to activation of p38 and JNK in several cellular systems, including MM. [31] [32] [33] [34] [35] [36] We confirmed that Pyk2-overxpression led to up-regulation of phospho(p)-p38 in MM cells; while Pyk2-silenging was responsible for p-p38 down-regulation together with p-JNK up-regulation (Supplemental Figure 4) .
We next interrogated whether Pyk2 silencing may enhance sensitivity to conventionally used anti-MM agents, such as bortezomib; and found that Pyk2 knock down MM.1S cells presented with significantly higher cytotoxicity when exposed to bortezomib, compared to scramble probe-infected cells that were used as control (Supplemental Figure 5A) . Moreover, it has been previously shown that Pyk2 mediates dexamethasone-induced apoptosis in MM cells. 31, 32 We therefore exposed Pyk2 overexpressing cells to increasing concentrations of dexamethasone and confirmed that Pyk2 gain of function enhanced dexamethasone-dependent cytotoxicity (Supplemental Figure 5B) .
It was previously shown that Pyk2 mediates cell migration. 14 Figure 6A-B) .
We next evaluated the anti-MM activity of VS-4718 using primary bone marrow-derived CD138+ MM cells as well as peripheral blood mononuclear cells (PBMCs) from healthy individuals, and found that VS-4718 exerted cytotoxicty against primary MM cells while this was not observed against normal PBMCs (Supplemental Figure 7A-B) .
We further verified the inhibitory effect of VS-4718 on MM tumor growth in vivo. We finally tested additional Pyk2-silenced RPMI.8226 cells in vivo, using a sub-cutaneous xenograft model; and found that Pyk2-loss of function led to inhibited tumor growth in vivo, compared to scramble probe-infected cells (Fig. 6G) .
DISCUSSION
In the present study, we demonstrated that Pyk2 but not FAK is overexpressed in MM patients and that specific subgroups of patients with deletion of chromosomal 8p21 may not express Pyk2, however most patients show higher expression during progression from MGUS stages to overt MM, 27 . In functional experiments, we show that inhibition of Pyk2 by RNA interference or Wnt/β-catenin signaling is well-known to promote tumorigenesis in both solid tumor and hematologic malignancies, specifically Multiple Myeloma. 37 In MM disease progression, accumulation of β -catenin in the nucleus of MM cells has been validated to promote MM cell proliferation, migration and invasion. [38] [39] [40] Pyk2 has been previously associated with activation of β -catenin: it promotes β -catenin nuclear translocation by phosphorylating β -catenin on tyrosine residues; 41 and associates with the Wnt5a/Frizzled-4/LRP5 complex, leading to the downstream activation of β -catenin. 42 Similarly, c-Myc and Cyclin D1 have shown oncogenic activity in MM leading to tumor progression and aggressive disease behavior. 43, 44 . We believe that Pyk2 regulates c-Myc and Cyclin D1 through modulation of Wnt/β-catenin signaling. Indeed, our finding demonstrates that Pyk2 protects β -catenin from GSK3β-induced degradation, thus leading to accumulation and translocation of β -catenin to the nucleus, which is essential for initiating transcription of Cyclin D1, c-Myc known to contribute to cell survival and proliferation.
Previous reports have dissected the role of Pyk2 in MM in vitro, indicating that Pyk2 may mediate dexamethasone-induced apoptosis. 31, 32 Our findings have further dissected the role of Pyk2 in MM by performing in vivo studies, thus accounting for the effect of the BM niche that is known to play a crucial role in MM pathogenesis and disease progression. Therefore, the demonstration that Pyk2 overexpressing cells present with an enhanced in vivo tumor growth may result not only from the direct Pyk2-dependent effect on the tumor clone itself, but also from the effect of the surrounding BM milieu on Pyk2 overexpressing cells.
Many studies have attempted to identify tyrosine kinase targets in MM as it promises a viable therapeutic target. Here, we demonstrate that Pyk2 is a promising therapeutic target in MM. Pyk2 expression is limited to specific cell types including hematopoietic cells, and therefore inhibition of Pyk2 is not expected to confer generalized toxicity. Interestingly, we found that silencing of FAK had no influence on MM tumor growth in vivo, which highlights the specific role of Pyk2 in mediating MM progression. The anti-tumor activity of dual FAK/Pyk2 inhibitors has been substantiated in several tumors overexpressing both FAK and Pyk2, [45] [46] [47] , and this study adds MM as an additional promising indication for a clinical stage FAK/PYK2
inhibitor, such as VS-4718. VS-4718 (former PND-1186) has been previously described as a FAK inhibitor, 24-26 and we are now reporting its inhibitory activity against Pyk2 which led to inhibition of MM cell growth both in vitro and in vivo. In addition, since Pyk2 inhibitors may be potentially applicable as a bone anabolic approach for osteoporosis due to enhancement of bone formation, 16 we could anticipate that Pyk2 inhibitor treatment may also help in treatment of myeloma bone disease.
In 
